866-997-4948(US-Canada Toll Free)

Metastatic Melanoma - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Oncology

No. of Pages : 502 Pages


Global Markets Directs, Metastatic Melanoma Pipeline Review, H1 2015, provides an overview of the Metastatic Melanomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 7
List of Figures 10

Introduction 11
Global Markets Direct Report Coverage 11
Metastatic Melanoma Overview 12
Therapeutics Development 13
Pipeline Products for Metastatic Melanoma - Overview 13
Pipeline Products for Metastatic Melanoma - Comparative Analysis 14
Metastatic Melanoma - Therapeutics under Development by Companies 15
Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 22
Metastatic Melanoma - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Metastatic Melanoma - Products under Development by Companies 27
Metastatic Melanoma - Products under Investigation by Universities/Institutes 35
Metastatic Melanoma - Companies Involved in Therapeutics Development 36
AB Science 36
AbbVie Inc. 37
Adaptimmune Limited 38
Affichem 39
Agalimmune Ltd 40
Agenus, Inc. 41
Altor BioScience Corporation 42
Amgen Inc. 43
Astex Pharmaceuticals, Inc. 44
AstraZeneca PLC 45
AVAX Technologies, Inc. 46
Bayer AG 47
Bioncotech Therapeutics S.L. 48
Bionomics Limited 49
Boehringer Ingelheim GmbH 50
Bristol-Myers Squibb Company 51
Cancer Therapeutics CRC Pty Ltd 52
Cavion LLC 53
Celgene Corporation 54
Celldex Therapeutics, Inc. 55
Colby Pharmaceutical Company 56
CureTech Ltd. 57
Delcath Systems, Inc. 58
Digna Biotech, S.L. 59
DNA Therapeutics S.A. 60
Eisai Co., Ltd. 61
Eli Lilly and Company 62
F. Hoffmann-La Roche Ltd. 63
Galapagos NV 64
Galectin Therapeutics, Inc. 65
GlaxoSmithKline plc 66
HanAll Biopharma Co., Ltd. 67
Immune Design Corp. 68
Immunophotonics Inc 69
ImmuRx, Inc. 70
Incyte Corporation 71
Life Science Pharmaceuticals, Incorporated 72
Lipotek Pty Ltd. 73
Luitpold Pharmaceuticals, Inc. 74
MedImmune, LLC 75
Merck & Co., Inc. 76
Merck KGaA 77
Momenta Pharmaceuticals, Inc. 78
Morphotek, Inc. 79
NeoStem, Inc. 80
NewLink Genetics Corporation 81
Novartis AG 82
Omeros Corporation 83
Oncolytics Biotech Inc. 84
OncoSec Medical Inc. 85
Ono Pharmaceutical Co., Ltd. 86
Onxeo SA 87
Pfizer Inc. 88
Philogen S.p.A. 89
Plexxikon Inc. 90
Polyphor Ltd. 91
Provectus Biopharmaceuticals, Inc. 92
Provenance Biopharmaceuticals Corp. 93
Reata Pharmaceuticals, Inc. 94
Recombio S.L 95
Sanofi 96
SBI Biotech Co., Ltd. 97
Scancell Holdings Plc 98
Takara Bio Inc. 99
Takeda Oncology 100
Ultimovacs AS 101
Vaxeal Holding SA 102
Vical Incorporated 103
WntResearch AB 104
ZIOPHARM Oncology, Inc. 105
Metastatic Melanoma - Therapeutics Assessment 106
Assessment by Monotherapy Products 106
Assessment by Combination Products 107
Assessment by Target 108
Assessment by Mechanism of Action 115
Assessment by Route of Administration 120
Assessment by Molecule Type 122
Drug Profiles 124
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 124
4-Peptide Melanoma Vaccine - Drug Profile 126
A-dmDT390-bisFv - Drug Profile 127
Ad-RTS-IL-12 - Drug Profile 128
AF-122 - Drug Profile 130
ALT-801 - Drug Profile 131
ALT-803 - Drug Profile 133
AMG-232 - Drug Profile 135
Anti-CSPG4-IL2 - Drug Profile 136
austrasulfone - Drug Profile 137
axitinib - Drug Profile 138
BA-015 - Drug Profile 141
bevacizumab - Drug Profile 143
BGJ-398 - Drug Profile 148
binimetinib + encorafenib - Drug Profile 149
BL-011256 - Drug Profile 151
BNC-420 - Drug Profile 152
BO-110 - Drug Profile 153
buparlisib hydrochloride - Drug Profile 154
Cancer Stem Cell Therapy - Drug Profile 158
capmatinib - Drug Profile 159
Cell Therapy to Target HERV-K for Metastatic Melanoma - Drug Profile 161
Cell Therapy to Target Melanoma Antigen Recognized By T-Cells 1 for Metastatic Melanoma - Drug Profile 162
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 163
Cell Therapy to Target NY-ESO-1 for Metastatic Melanoma - Drug Profile 165
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 166
cobimetinib - Drug Profile 167
contego - Drug Profile 171
CPC-410 - Drug Profile 173
dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 174
Darleukin - Drug Profile 175
DB-039 - Drug Profile 177
Dendritic Cell Therapy 2 for Metastatic Melanoma - Drug Profile 178
Dendritic Cell Therapy for Metastatic Melanoma - Drug Profile 179
Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma - Drug Profile 180
Dendritic Cell Therapy to Target gp100, Melan-A, MAGEA3 and Tyrosinase for Metastatic Melanoma - Drug Profile 181
Dendritic Cell Therapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma - Drug Profile 182
DNA IL-12 - Drug Profile 183
DT-01 - Drug Profile 185
E-6201 - Drug Profile 187
ecromeximab - Drug Profile 189
eltrapuldencel-T - Drug Profile 190
encorafenib - Drug Profile 192
G-305 - Drug Profile 194
glembatumumab vedotin - Drug Profile 195
GLPG-1790 - Drug Profile 197
GR-MD-02 - Drug Profile 198
GSK-2132231A - Drug Profile 200
GSK-2241658A - Drug Profile 201
GSK-2302025A - Drug Profile 202
HF-10 - Drug Profile 203
HL-156CAN - Drug Profile 204
HL-176 - Drug Profile 205
HL-177 - Drug Profile 206
ICOVIR-5 - Drug Profile 207
INCB-24360 - Drug Profile 208
inCVAX - Drug Profile 210
indoximod - Drug Profile 212
ipilimumab - Drug Profile 214
lenvatinib - Drug Profile 218
Lipovaxin-MM - Drug Profile 222
LOC-paclitaxel - Drug Profile 223
LV-305 - Drug Profile 224
LY-3009120 - Drug Profile 225
M-200 - Drug Profile 226
M-Vax - Drug Profile 227
masitinib - Drug Profile 229
melphalan - Drug Profile 232
MelVax - Drug Profile 234
mibefradil dihydrochloride - Drug Profile 235
miRNA-7-5p - Drug Profile 237
MLN-2480 - Drug Profile 238
Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma - Drug Profile 240
MORAb-050 - Drug Profile 241
MSX-122 - Drug Profile 242
NAcGM3/VSSP Vaccine - Drug Profile 244
necuparanib - Drug Profile 246
nilotinib - Drug Profile 247
nintedanib - Drug Profile 250
nivolumab (recombinant) - Drug Profile 254
onalespib - Drug Profile 259
ontuxizumab - Drug Profile 262
paclitaxel albumin bound - Drug Profile 264
palbociclib - Drug Profile 268
pasireotide - Drug Profile 272
pelareorep - Drug Profile 275
pembrolizumab - Drug Profile 280
pevonedistat hydrochloride - Drug Profile 284
pidilizumab - Drug Profile 286
pimasertib hydrochloride - Drug Profile 288
PLX-3397 - Drug Profile 290
POL-7085 - Drug Profile 292
PV-10 - Drug Profile 293
Q-204 - Drug Profile 296
RAF-265 - Drug Profile 297
Recombinant Protein for Metastatic Melanoma - Drug Profile 298
Recombinant Protein for Oncology - Drug Profile 299
RG-7446 - Drug Profile 300
Riluzole Prodrugs - Drug Profile 302
RTA-408 - Drug Profile 303
SAGEs for Cancer - Drug Profile 306
sagopilone - Drug Profile 307
SAR-260301 - Drug Profile 309
SCIB-1 - Drug Profile 310
selumetinib sulfate - Drug Profile 313
Small Molecule to Antagonize GPR19 for Metastatic Melanoma - Drug Profile 316
Small Molecules to Antagonize ET-B for Oncology - Drug Profile 317
Small Molecules to Inhibit FAK-FLT3-VEGFR3 for Oncology - Drug Profile 318
sunitinib malate - Drug Profile 319
SVX-1 - Drug Profile 323
Synthetic Peptide for Malignant Melanoma - Drug Profile 324
TAK-733 - Drug Profile 325
talimogene laherparepvec - Drug Profile 327
TMECG - Drug Profile 330
TPI-287 - Drug Profile 331
tremelimumab + MEDI-3617 - Drug Profile 333
UV-1 - Drug Profile 334
Vaccine for Cancer - Drug Profile 335
Vaccine for Metastatic Melanoma - Drug Profile 336
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 337
varlilumab - Drug Profile 338
velimogene aliplasmid - Drug Profile 340
veliparib - Drug Profile 343
vemurafenib - Drug Profile 346
ZSG-101 - Drug Profile 349
ZSG-102 - Drug Profile 350
Metastatic Melanoma - Recent Pipeline Updates 351
Metastatic Melanoma - Dormant Projects 473
Metastatic Melanoma - Discontinued Products 483
Metastatic Melanoma - Product Development Milestones 484
Featured News & Press Releases 484

Appendix 492
Methodology 492
Coverage 492
Secondary Research 492
Primary Research 492
Expert Panel Validation 492
Contact Us 492
Disclaimer 493

List of Table


Number of Products under Development for Metastatic Melanoma, H1 2015 22
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2015 23
Number of Products under Development by Companies, H1 2015 25
Number of Products under Development by Companies, H1 2015 (Contd..1) 26
Number of Products under Development by Companies, H1 2015 (Contd..2) 27
Number of Products under Development by Companies, H1 2015 (Contd..3) 28
Number of Products under Development by Companies, H1 2015 (Contd..4) 29
Number of Products under Development by Companies, H1 2015 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2015 32
Comparative Analysis by Late Stage Development, H1 2015 33
Comparative Analysis by Clinical Stage Development, H1 2015 34
Comparative Analysis by Early Stage Development, H1 2015 35
Products under Development by Companies, H1 2015 36
Products under Development by Companies, H1 2015 (Contd..1) 37
Products under Development by Companies, H1 2015 (Contd..2) 38
Products under Development by Companies, H1 2015 (Contd..3) 39
Products under Development by Companies, H1 2015 (Contd..4) 40
Products under Development by Companies, H1 2015 (Contd..5) 41
Products under Development by Companies, H1 2015 (Contd..6) 42
Products under Development by Companies, H1 2015 (Contd..7) 43
Products under Investigation by Universities/Institutes, H1 2015 44
Metastatic Melanoma - Pipeline by AB Science, H1 2015 45
Metastatic Melanoma - Pipeline by AbbVie Inc., H1 2015 46
Metastatic Melanoma - Pipeline by Adaptimmune Limited, H1 2015 47
Metastatic Melanoma - Pipeline by Affichem, H1 2015 48
Metastatic Melanoma - Pipeline by Agalimmune Ltd, H1 2015 49
Metastatic Melanoma - Pipeline by Agenus, Inc., H1 2015 50
Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H1 2015 51
Metastatic Melanoma - Pipeline by Amgen Inc., H1 2015 52
Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 53
Metastatic Melanoma - Pipeline by AstraZeneca PLC, H1 2015 54
Metastatic Melanoma - Pipeline by AVAX Technologies, Inc., H1 2015 55
Metastatic Melanoma - Pipeline by Bayer AG, H1 2015 56
Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2015 57
Metastatic Melanoma - Pipeline by Bionomics Limited, H1 2015 58
Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 59
Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2015 60
Metastatic Melanoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 61
Metastatic Melanoma - Pipeline by Cavion LLC, H1 2015 62
Metastatic Melanoma - Pipeline by Celgene Corporation, H1 2015 63
Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2015 64
Metastatic Melanoma - Pipeline by Colby Pharmaceutical Company, H1 2015 65
Metastatic Melanoma - Pipeline by CureTech Ltd., H1 2015 66
Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H1 2015 67
Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H1 2015 68
Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H1 2015 69
Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H1 2015 70
Metastatic Melanoma - Pipeline by Eli Lilly and Company, H1 2015 71
Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 72
Metastatic Melanoma - Pipeline by Galapagos NV, H1 2015 73
Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H1 2015 74
Metastatic Melanoma - Pipeline by GlaxoSmithKline plc, H1 2015 75
Metastatic Melanoma - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 76
Metastatic Melanoma - Pipeline by Immune Design Corp., H1 2015 77
Metastatic Melanoma - Pipeline by Immunophotonics Inc, H1 2015 78
Metastatic Melanoma - Pipeline by ImmuRx, Inc., H1 2015 79
Metastatic Melanoma - Pipeline by Incyte Corporation, H1 2015 80
Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2015 81
Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H1 2015 82
Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H1 2015 83
Metastatic Melanoma - Pipeline by MedImmune, LLC, H1 2015 84
Metastatic Melanoma - Pipeline by Merck & Co., Inc., H1 2015 85
Metastatic Melanoma - Pipeline by Merck KGaA, H1 2015 86
Metastatic Melanoma - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 87
Metastatic Melanoma - Pipeline by Morphotek, Inc., H1 2015 88
Metastatic Melanoma - Pipeline by NeoStem, Inc., H1 2015 89
Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H1 2015 90
Metastatic Melanoma - Pipeline by Novartis AG, H1 2015 91
Metastatic Melanoma - Pipeline by Omeros Corporation, H1 2015 92
Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H1 2015 93
Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H1 2015 94
Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 95
Metastatic Melanoma - Pipeline by Onxeo SA, H1 2015 96
Metastatic Melanoma - Pipeline by Pfizer Inc., H1 2015 97
Metastatic Melanoma - Pipeline by Philogen S.p.A., H1 2015 98
Metastatic Melanoma - Pipeline by Plexxikon Inc., H1 2015 99
Metastatic Melanoma - Pipeline by Polyphor Ltd., H1 2015 100
Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 101
Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2015 102
Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 103
Metastatic Melanoma - Pipeline by Recombio S.L, H1 2015 104
Metastatic Melanoma - Pipeline by Sanofi, H1 2015 105
Metastatic Melanoma - Pipeline by SBI Biotech Co., Ltd., H1 2015 106
Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H1 2015 107
Metastatic Melanoma - Pipeline by Takara Bio Inc., H1 2015 108
Metastatic Melanoma - Pipeline by Takeda Oncology, H1 2015 109
Metastatic Melanoma - Pipeline by Ultimovacs AS, H1 2015 110
Metastatic Melanoma - Pipeline by Vaxeal Holding SA, H1 2015 111
Metastatic Melanoma - Pipeline by Vical Incorporated, H1 2015 112
Metastatic Melanoma - Pipeline by WntResearch AB, H1 2015 113
Metastatic Melanoma - Pipeline by ZIOPHARM Oncology, Inc., H1 2015 114
Assessment by Monotherapy Products, H1 2015 115
Assessment by Combination Products, H1 2015 116
Number of Products by Stage and Target, H1 2015 118
Number of Products by Stage and Mechanism of Action, H1 2015 125
Number of Products by Stage and Route of Administration, H1 2015 130
Number of Products by Stage and Molecule Type, H1 2015 132
Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H1 2015 360
Metastatic Melanoma - Dormant Projects, H1 2015 482
Metastatic Melanoma - Dormant Projects (Contd..1), H1 2015 483
Metastatic Melanoma - Dormant Projects (Contd..2), H1 2015 484
Metastatic Melanoma - Dormant Projects (Contd..3), H1 2015 485
Metastatic Melanoma - Dormant Projects (Contd..4), H1 2015 486
Metastatic Melanoma - Dormant Projects (Contd..5), H1 2015 487
Metastatic Melanoma - Dormant Projects (Contd..6), H1 2015 488
Metastatic Melanoma - Dormant Projects (Contd..7), H1 2015 489
Metastatic Melanoma - Dormant Projects (Contd..8), H1 2015 490
Metastatic Melanoma - Dormant Projects (Contd..9), H1 2015 491
Metastatic Melanoma - Discontinued Products, H1 2015 492

List of Chart


Number of Products under Development for Metastatic Melanoma, H1 2015 22
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2015 23
Number of Products under Development by Companies, H1 2015 24
Number of Products under Investigation by Universities/Institutes, H1 2015 31
Comparative Analysis by Late Stage Development, H1 2015 33
Comparative Analysis by Clinical Stage Development, H1 2015 34
Comparative Analysis by Early Stage Products, H1 2015 35
Assessment by Monotherapy Products, H1 2015 115
Assessment by Combination Products, H1 2015 116
Number of Products by Top 10 Targets, H1 2015 117
Number of Products by Stage and Top 10 Targets, H1 2015 117
Number of Products by Top 10 Mechanism of Actions, H1 2015 124
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 124
Number of Products by Top 10 Routes of Administration, H1 2015 129
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 129
Number of Products by Top 10 Molecule Types, H1 2015 131
Number of Products by Stage and Top 10 Molecule Types, H1 2015 131

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *